A Study of LY900014 Versus Insulin Lispro (Humalog) on High Blood Sugar in Participants With Type 1 Diabetes Who Use Insulin Pumps
A Study of LY900014 Versus Insulin Lispro (Humalog) on High Blood Sugar in Participants With Type 1 Diabetes Who Use Insulin Pumps
The main purpose of this study is to compare LY900014 to insulin lispro (Humalog) in
 participants with type 1 diabetes who are using an insulin pump and have high blood sugar
 after eating. For each participant, the study will last about two to nine weeks.
Inclusion Criteria:

 -  Male or female participants with type 1 diabetes

 -  Body mass index (BMI) between 18.5 and 30.0 kilograms per square meter, inclusive

 -  Hemoglobin A1c (HbA1c) less than or equal to 8.5 percent (%)

 -  Using CSII and stable insulin regimen for at least 3 months prior to inclusion into
 the trial

 Exclusion Criteria:

 -  Known or suspected hypersensitivity to investigational medical product(s) or related
 products

 -  Receipt of any medicinal product in clinical development within 30 days or at least 5
 half-lives of the related substances and their metabolites (whichever is longer)
 before randomization in this trial

 -  Known slowing of gastric emptying and or gastrointestinal surgery that, in the opinion
 of the investigator, might change gastrointestinal motility and food absorption

 -  Proliferative retinopathy or maculopathy as judged by the Investigator based on a
 recent (less than 1.5 years) ophthalmologic examination

 -  Widespread subcutaneous lipodystrophy in the abdomen

 -  Current use of any glucose-lowering agents other than insulin within 3 months prior to
 screening

 -  Chronic or recent use of corticosteroids